Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Enforced sialyl-Lewis-X (sLeX) display in E-selectin ligands by exofucosylation is dispensable for CD19-CAR T-cell activity and bone marrow homing

  • Sánchez Martínez, Diego|||0000-0003-4605-5325
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Romecín, Paola Alejandra|||0000-0001-6890-5883
  • Vinyoles, Meritxell|||0000-0003-1906-4701
  • Palomo, Marta|||0000-0002-3261-6577
  • Tirado, Néstor
  • Zanetti, S. R.|||0000-0002-9052-8751
  • Juan, Manel|||0000-0002-3064-1648
  • Carlet, Michela
  • Jeremias, Irmela|||0000-0003-1773-7677
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
CD19-directed chimeric antigen receptors (CAR) T cells induce impressive rates of complete response in advanced B-cell malignancies, specially in B-cell acute lymphoblastic leukemia (B-ALL). However, CAR T-cell-treated patients eventually progress due to poor CAR T-cell persistence and/or disease relapse. The bone marrow (BM) is the primary location for acute leukemia. The rapid/efficient colonization of the BM by systemically infused CD19-CAR T cells might enhance CAR T-cell activity and persistence, thus, offering clinical benefits. Circulating cells traffic to BM upon binding of tetrasaccharide sialyl-Lewis X (sLeX)-decorated E-selectin ligands (sialofucosylated) to the E-selectin receptor expressed in the vascular endothelium. sLeX-installation in E-selectin ligands is achieved through an ex vivo fucosylation reaction. Here, we sought to characterize the basal and cell-autonomous display of sLeX in CAR T-cells activated using different cytokines, and to assess whether exofucosylation of E-selectin ligands improves CD19-CAR T-cell activity and BM homing. We report that cell-autonomous sialofucosylation (sLeX display) steadily increases in culture- and in vivo -expanded CAR T cells, and that, the cytokines used during T-cell activation influence both the degree of such endogenous sialofucosylation and the CD19-CAR T-cell efficacy and persistence in vivo. However, glycoengineered enforced sialofucosylation of E-selectin ligands was dispensable for CD19-CAR T-cell activity and BM homing in multiple xenograft models regardless the cytokines employed for T-cell expansion, thus, representing a dispensable strategy for CD19-CAR T-cell therapy. Glyco-engineered enforced sialofucosylation of E-selectin ligands was dispensable for CD19-CAR T-cell activity and BM homing in multiple xenograft models, thus representing an unnecessary strategy for CD19-CAR T-cell therapy
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia

  • Sánchez Martínez, Diego|||0000-0003-4605-5325
  • Tirado, Nestor|||0000-0001-8352-2194
  • Mensurado, Sofía|||0000-0002-5157-0033
  • Martínez Moreno, Alba|||0000-0001-7514-260X
  • Romecín, Paola Alejandra|||0000-0001-6890-5883
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Correia, Daniel V.|||0000-0002-0784-0307
  • Silva-Santos, Bruno|||0000-0003-4141-9302
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Background Chimeric antigen receptor (CAR)-T cells have emerged as a breakthrough treatment for relapse/refractory hematological tumors, showing impressive complete remission rates. However, around 50% of the patients relapse before 1-year post-treatment. T-cell 'fitness' is critical to prolong CAR-T persistence and activity. Allogeneic T cells from healthy donors are less dysfunctional or exhausted than autologous patientderived T cells; in this context, Delta One T cells (DOTs), a recently described cellular product based on MHC/ HLA-independent Vδ1+ γδ T cells, represent a promising allogeneic platform. Methods Here we generated and preclinically validated, for the first time, 4-1BB-based CAR-DOTs directed against the interleukin-3α chain receptor (CD123), a target antigen widely expressed on acute myeloid leukemia (AML) blasts. Results CD123CAR-DOTs showed vigorous, superior to control DOTs, cytotoxicity against AML cell lines and primary samples both in vitro and in vivo, even on tumor rechallenge. Conclusions Our results provide the proof-of-concept for a DOT-based next-generation allogeneic CAR-T therapy for AML.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells

  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Trincado Alonso, Juan Luis, 1987-|||0000-0001-5363-3774
  • Vinyoles, Meritxell|||0000-0003-1906-4701
  • Closa, Adria|||0000-0002-9302-337X
  • Martínez Moreno, Alba|||0000-0001-7514-260X
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Molina, Oscar|||0000-0001-7585-4519
  • Rodríguez-Cortez, Virginia Carolina|||0000-0002-0853-247X
  • Ximeno-Parpal, Pau|||0000-0003-1814-9607
  • Fernández Fuentes, Narcís|||0000-0002-6421-1080
  • Petazzi, Paolo|||0000-0002-1036-2895
  • Beneyto Calabuig, Sergi|||0000-0003-3773-8239
  • Velten, Lars
  • Romecín, Paola Alejandra|||0000-0001-6890-5883
  • Casquero, Raquel
  • Abollo-Jiménez, Fernando
  • de la Guardia, Rafael D.
  • Lorden, Patricia
  • Bataller, Alex|||0000-0002-6085-2745
  • Lapillonne, Hélène|||0000-0002-6900-8313
  • Stam, Ronald W.
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Torrebadell, Montserrat
  • Fuster, José Luis|||0000-0002-4881-9440
  • Bueno, Clara|||0000-0003-1442-6216
  • Sarry, Jean Emmanuel
  • Eyras, Eduardo|||0000-0003-0793-6218
  • Heyn, Holger|||0000-0002-3276-1889
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Relapse remains a major challenge in the clinical management of acute myeloid leukemia (AML) and is driven by rare therapy-resistant leukemia stem cells (LSCs) that reside in specific bone marrow niches. Hypoxia signaling maintains cells in a quiescent and metabolically relaxed state, desensitizing them to chemotherapy. This suggests the hypothesis that hypoxia contributes to the chemoresistance of AML-LSCs and may represent a therapeutic target to sensitize AML-LSCs to chemotherapy. Here, we identify HIF and HIF specific AML subgroups (inv(16)/t(8;21) and MLLr, respectively) and provide a comprehensive single-cell expression atlas of 119,000 AML cells and AML-LSCs in paired diagnostic-relapse samples from these molecular subgroups. The HIF/hypoxia pathway signature is attenuated in AML-LSCs compared with more differentiated AML cells but is more expressed than in healthy hematopoietic cells. Importantly, chemical inhibition of HIF cooperates with standard-of-care chemotherapy to impair AML growth and to substantially eliminate AML-LSCs in vitro and in vivo. These findings support the HIF pathway in the stem cell-driven drug resistance of AML and unravel avenues for combinatorial targeted and chemotherapy-based approaches to specifically eliminate AML-LSCs.